About 15 years ago, I traveled to nutley, N.J., to interview a molecular biologist at Hoffmann-La Roche. I vividly recall my host waving at an impressive little skyline of build- ings worthy of a college quadrangle and proudly saying, "Valium built all this." As recently as a month ago, when I visited the gleaming research and development complex of SmithKline Beecham just outside Philadelphia, my scientific host waved at an expanse of tinted-glass buildings and explained, "Tagamet paid for all of this."
展开▼
